Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Neutral

CardioComm Solutions and Predictiv AI Enter into Strategic AI Collaboration

Micro-cap ECG software developer pivoting to AI-driven remote monitoring amid persistent cash burn and negative equity.

By The Northwire Desk — AI Analysis Jun 08, 2026 · 09:12 EKG · 0.01 CardioComm Solutions, Inc.
Executive Summary
  • CardioComm Solutions entered a strategic collaboration, joint development, and intellectual property agreement with Predictiv AI Inc. on June 8, 2026.
  • The partnership aims to combine Predictiv AI's telemetry, data intelligence, and predictive analytics with CardioComm's proprietary ECG management software, regulatory expertise, and commercialization experience.
  • The agreement is a high-level framework; specific project deliverables, budgets, timelines, and commercial terms will be negotiated via separate definitive agreements.
  • CardioComm retains final decision-making authority over regulatory, quality, cybersecurity, and release matters for any regulated medical software/SaMD.
  • CEO Etienne Grima recused himself from the Board's consideration due to his concurrent directorship at Predictiv AI.
Material Impact
  • The announcement is a strategic framework rather than a binding commercial contract with immediate financial implications.
  • It aligns with the company's stated goal to commercialize its flagship GEMS FLEX and 14-day Holter/Event LTCM ECG platform, but provides no new revenue, margin, or cash flow data.
  • Given the company's micro-cap status and historical reliance on related-party financing, this collaboration is incremental and expected. It does not alter the fundamental cash burn or capital structure in the near term.
  • The market has already priced the stock in a tight $0.01–$0.02 range for over a year, indicating that incremental strategic announcements of this nature are viewed as routine by participants.
EKG · Price
Company Overview
  • CardioComm Solutions develops proprietary medical software, ECG management technologies, and remote patient monitoring solutions.
  • The company is focused on bringing its flagship GEMS FLEX and 14-day Holter/Event LTCM ECG platform to market, targeting healthcare providers for efficient medical data review and clinical event identification.
  • The business model relies on software-as-a-medical-device (SaMD) sales and partnerships, with a heavy emphasis on AI-driven analytics and workflow optimization.
  • Management maintains strict control over regulatory and quality compliance (ISO 13485 and ISO 27001) for all medical software projects.
Read the original news release →

More from CardioComm Solutions, Inc.

Nov 10, 2025 · 23:37

CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility

Financings Nov 04, 2025 · 00:40

CardioComm Terminates Royalty Agreement and Enters into $512,000 Insider Loan Facility to Advance Gems Flex and 14-Day Holter/LTCM Platform

Financings